Table 1 Baseline clinical characteristics of placebo patients with centrally confirmed HER2+ breast cancer in TEACH
From: Long-term hazard of recurrence in HER2+ breast cancer patients untreated with anti-HER2 therapy
N (%) | |||
|---|---|---|---|
All | HR− | HR+ | |
( N = 1,260) | ( N = 561) | ( N = 699) | |
Median age, yrs (range) | 50 (22–81) | 51 (24–81) | 48 (22–80) |
Age range (%) | |||
<40 | 217 (17) | 78 (14) | 139 (20) |
40-50 | 446 (36) | 160 (28) | 286 (41) |
50-60 | 414 (33) | 224 (40) | 190 (27) |
60-70 | 155 (12) | 83 (15) | 72 (10) |
>70 | 28 (2) | 16 (3) | 12 (2) |
Postmenopausal, n (%) | 854 (68) | 403 (72) | 451 (65) |
Race, n (%) | |||
White | 840 (67) | 370 (66) | 470 (67) |
Asian | 298 (23) | 135 (24) | 163 (23) |
Black | 35 (3) | 16 (3) | 19 (3) |
Other/unknown | 87 (7) | 40 (7) | 47 (7) |
Median time since initial diagnosis, yrs (range) | 3 (0–15) | 2 (0–15) | 3 (0–12) |
Years since initial diagnosis, n (%) | |||
≤4 | 916 (73) | 430 (77) | 486 (70) |
>4 | 344 (27) | 131 (23) | 213 (30) |
0-1 | 278 (22) | 138 (25) | 140 (20) |
Hormone receptor status, n (%) | |||
HR+ (ER+ or PR+) | 695 (55) | - | 695 (100) |
ER+ and PR+ | 438 (35) | - | 438 (63) |
ER+ and PR- | 170 (13) | - | 170 (24) |
ER- and PR+ | 87 (7) | - | 87 (13) |
HR- (ER- and PR-) | 561 (45) | 561 (100) | - |
Nodal involvement, n (%) | 698 (57) | 303 (55) | 395 (58) |
Low stage (T1 N0), n (%) | 220 (18) | 92 (17) | 128 (19) |
Prior or concurrent endocrine therapy (HR+ only), n (%) | |||
Yes | 625 (50) | - | 625 (89) |
No | 74 (6) | - | 74 (11) |
N/A | 561 (45) | 561 (100) | - |
Adjuvant chemotherapy, n (%) | |||
Anthracycline without taxane | 710 (56) | 303 (54) | 407 (58) |
Anthracycline with taxane | 503 (40) | 234 (42) | 269 (39) |
No anthracycline | 47 (4) | 24 (4) | 23 (3) |